Also known as: C4 Therapeutics
C4 Therapeutics is a clinical-stage biopharmaceutical company developing degraders designed to eliminate disease-causing proteins. Its pipeline includes oncology candidates and collaborations with major pharmaceutical partners. The company was incorporated in 2015, is headquartered in Watertown, Massachusetts, and trades on Nasdaq as CCCC.
C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.
Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.
